Literature DB >> 6619251

High-performance liquid chromatographic analysis of tamoxifen and major metabolites in human plasma.

C M Camaggi, E Strocchi, N Canova, F Pannuti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6619251     DOI： 10.1016/s0378-4347(00)84393-5

Source DB:  PubMed          Journal:  J Chromatogr


× No keyword cloud information.
  7 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

2.  The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

Review 3.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

4.  Effect of combined therapy with the antiestrogen agent toremifene and local hyperthermia on breast cancer cells implanted in nude mice.

Authors:  Yoshiaki Kanaya; Hiroyoshi Doihara; Kouji Shiroma; Yutaka Ogasawara; Hiroshi Date
Journal:  Surg Today       Date:  2008-09-27       Impact factor: 2.549

5.  Tamoxifen metabolism is altered by simultaneous administration of medroxyprogesterone acetate in breast cancer patients.

Authors:  A D Reid; J M Horobin; E L Newman; P E Preece
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

6.  Medroxyprogesterone acetate (MAP) and tamoxifen (TMX) plasma levels after simultaneous treatment with 'low' TMX and 'high' MAP doses.

Authors:  C M Camaggi; E Strocchi; N Canova; B Costanti; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.

Authors:  G Milano; M C Etienne; M Frenay; R Khater; J L Formento; N Renee; J L Moll; M Francoual; M Berto; M Namer
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.